Conversely, patients with CAD who display elevated levels of CTRP5 and chemerin, minimal CAD extent, low CACS, and significant early-stage atherosclerotic plaque burden (without intraluminal stenosis) may also be identified by CCTA. Here, RARRES2 is linked to coronary artery disorder.